Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy
Jan Skupień(Harvard University), Andrzej S. Królewski(Joslin Diabetes Center), Tarunveer S. Ahluwalia(Steno Diabetes Centers), Carol Forsblom(University of Helsinki), Per‐Henrik Groop(University of Helsinki), Helen Nickerson(Breakthrough T1D), Erkka Valo(University of Helsinki), Samy Hadjadj(Université de Poitiers), Marcus G. Pezzolesi(University of Utah), Niina Sandholm(University of Helsinki), Valma Harjutsalo(Research Council of Finland), Adam M. Smiles(Joslin Diabetes Center), Stephanie Croall(Joslin Diabetes Center), Stephen S. Rich(Virginia Department of Health), David‐Alexandre Trégouët(Université de Bordeaux), Kevin McDonnell(University College Dublin), Peter Rossing(Steno Diabetes Centers), Beata Gyorgy(Inserm), Michel Marre(Centre National de la Recherche Scientifique), Maria Lajer(Steno Diabetes Centers), Andrzej T. Gałecki(University of Michigan), Josyf C. Mychaleckyj(University of Virginia Health System), Chun Yi Wu(University of Michigan), Marlon Pragnell(Breakthrough T1D)
Cited by 49
Related Papers
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
|New England Journal of Medicine|2024|1.5k